FI62099C - Foerfarande foer framstaellning av roentgenamorfisk aeskin - Google Patents
Foerfarande foer framstaellning av roentgenamorfisk aeskin Download PDFInfo
- Publication number
- FI62099C FI62099C FI761895A FI761895A FI62099C FI 62099 C FI62099 C FI 62099C FI 761895 A FI761895 A FI 761895A FI 761895 A FI761895 A FI 761895A FI 62099 C FI62099 C FI 62099C
- Authority
- FI
- Finland
- Prior art keywords
- aeskin
- framework
- ray
- research
- amorphous
- Prior art date
Links
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000002378 acidificating effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 2
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 2
- 241000157282 Aesculus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000002322 anti-exudative effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LBPGGVGNNLPHBO-UHFFFAOYSA-N [N].OC Chemical compound [N].OC LBPGGVGNNLPHBO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 238000005280 amorphization Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2530953A DE2530953C3 (de) | 1975-07-11 | 1975-07-11 | Verfahren zur Herstellung von röntgenamorphem Aescin, nach diesem Verfahren erhältliches röntgenamorphes Aescin und dieses enthaltende Arzneimittel |
| DE2530953 | 1975-07-11 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI761895A7 FI761895A7 (cs) | 1977-01-12 |
| FI62099B FI62099B (fi) | 1982-07-30 |
| FI62099C true FI62099C (fi) | 1982-11-10 |
Family
ID=5951225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI761895A FI62099C (fi) | 1975-07-11 | 1976-06-30 | Foerfarande foer framstaellning av roentgenamorfisk aeskin |
Country Status (20)
| Country | Link |
|---|---|
| JP (2) | JPS5234915A (cs) |
| AU (1) | AU510463B2 (cs) |
| BE (1) | BE844053A (cs) |
| BG (1) | BG27379A3 (cs) |
| CA (1) | CA1064903A (cs) |
| CS (1) | CS208184B2 (cs) |
| DE (1) | DE2530953C3 (cs) |
| ES (1) | ES449748A1 (cs) |
| FI (1) | FI62099C (cs) |
| FR (1) | FR2316961A1 (cs) |
| GB (1) | GB1550845A (cs) |
| HK (1) | HK33681A (cs) |
| HU (1) | HU174603B (cs) |
| PH (1) | PH13989A (cs) |
| PL (1) | PL99028B1 (cs) |
| PT (1) | PT65302B (cs) |
| RO (1) | RO70354A (cs) |
| SU (1) | SU786857A3 (cs) |
| YU (1) | YU41812B (cs) |
| ZA (1) | ZA764065B (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1252201B (it) * | 1991-12-12 | 1995-06-05 | Dompe Farmaceutici Spa | S-carbossimetilcisteina sale di lisina monoidrato e procedimento per la sua preparazione. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE302543C (cs) * | ||||
| NL301747A (cs) * | 1962-12-14 | |||
| YU37063B (en) * | 1971-12-06 | 1984-08-31 | Lek Tovarna Farmacevtskih | Process for preparing x-ray amorphous water-sulubleascin |
| DE2357226A1 (de) * | 1973-11-16 | 1975-05-28 | Merck Patent Gmbh | Verfahren zur herstellung von wasserloeslichem beta-aescin |
-
1975
- 1975-07-11 DE DE2530953A patent/DE2530953C3/de not_active Expired - Lifetime
-
1976
- 1976-06-30 FI FI761895A patent/FI62099C/fi not_active IP Right Cessation
- 1976-06-30 PT PT65302A patent/PT65302B/pt unknown
- 1976-07-05 BG BG033673A patent/BG27379A3/xx unknown
- 1976-07-07 SU SU762377645A patent/SU786857A3/ru active
- 1976-07-07 GB GB28233/76A patent/GB1550845A/en not_active Expired
- 1976-07-08 AU AU15729/76A patent/AU510463B2/en not_active Expired
- 1976-07-08 YU YU1670/76A patent/YU41812B/xx unknown
- 1976-07-08 ZA ZA764065A patent/ZA764065B/xx unknown
- 1976-07-09 CS CS764567A patent/CS208184B2/cs unknown
- 1976-07-09 HU HU76MA2797A patent/HU174603B/hu not_active IP Right Cessation
- 1976-07-09 CA CA256,650A patent/CA1064903A/en not_active Expired
- 1976-07-10 PL PL1976191114A patent/PL99028B1/pl unknown
- 1976-07-10 ES ES449748A patent/ES449748A1/es not_active Expired
- 1976-07-10 RO RO7686932A patent/RO70354A/ro unknown
- 1976-07-12 PH PH18678A patent/PH13989A/en unknown
- 1976-07-12 JP JP51082846A patent/JPS5234915A/ja active Granted
- 1976-07-12 FR FR7621313A patent/FR2316961A1/fr active Granted
- 1976-07-12 BE BE168849A patent/BE844053A/xx not_active IP Right Cessation
-
1981
- 1981-07-16 HK HK336/81A patent/HK33681A/xx unknown
-
1986
- 1986-12-22 JP JP61304058A patent/JPS6366127A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AU1572976A (en) | 1978-01-12 |
| FR2316961B1 (cs) | 1984-04-20 |
| PT65302B (de) | 1977-12-13 |
| ZA764065B (en) | 1977-07-27 |
| PH13989A (en) | 1980-11-28 |
| SU786857A3 (ru) | 1980-12-07 |
| JPS5234915A (en) | 1977-03-17 |
| JPS6366127A (ja) | 1988-03-24 |
| CS208184B2 (en) | 1981-08-31 |
| RO70354A (ro) | 1982-03-24 |
| FI62099B (fi) | 1982-07-30 |
| AU510463B2 (en) | 1980-06-26 |
| HK33681A (en) | 1981-07-24 |
| YU167076A (en) | 1983-06-30 |
| FI761895A7 (cs) | 1977-01-12 |
| DE2530953A1 (de) | 1977-01-27 |
| GB1550845A (en) | 1979-08-22 |
| YU41812B (en) | 1988-02-29 |
| HU174603B (hu) | 1980-02-28 |
| DE2530953C2 (de) | 1994-07-07 |
| CA1064903A (en) | 1979-10-23 |
| DE2530953C3 (de) | 1994-07-07 |
| PT65302A (de) | 1976-07-01 |
| BG27379A3 (bg) | 1979-10-12 |
| BE844053A (fr) | 1977-01-12 |
| PL99028B1 (pl) | 1978-06-30 |
| FR2316961A1 (fr) | 1977-02-04 |
| JPH0336808B2 (cs) | 1991-06-03 |
| ES449748A1 (es) | 1977-08-16 |
| JPS6221765B2 (cs) | 1987-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3041803B2 (ja) | 植物またはその抽出物からアントシアノシド類を高純度で含有する抽出物の調製方法 | |
| Cwiertnia et al. | Stability of diclofenac sodium in the inclusion complex with β-cyclodextrin in the solid state | |
| WO2017133465A1 (zh) | 一种黄芩苷镁化合物及其制备方法与它的用途 | |
| CN102627605A (zh) | 石杉碱甲多晶型体、其制备方法、包含所述多晶型体的药物组合物及其用途 | |
| CN108732259A (zh) | 荭草花提取物中入血化学成分的检测方法 | |
| FI62099B (fi) | Foerfarande foer framstaellning av roentgenamorfisk aeskin | |
| ES2559863T3 (es) | Nuevo procedimiento de preparación de extractos purificados de Harpagophytum procumbens | |
| CN104031030A (zh) | 一种右旋雷贝拉唑钠单水合物晶型及其制备方法 | |
| CN110330410A (zh) | 一种和厚朴酚葡甲胺共晶及其制备方法 | |
| AU654583B2 (en) | Antineoplastic drug of plant extraction and process for the preparation thereof | |
| Wang et al. | Microcrystalline preparation of akebia saponin D for its bioavailability enhancement in rats | |
| CN104906191A (zh) | 宽筋藤乙酰胆碱酯酶抑制活性提取物及其组合物的医药用途和制备方法 | |
| KR960014790B1 (ko) | 선택성이 높고 독성이 크게 감소된 식물 유래의 항신생물 화학요법제 및 그의 제조방법 | |
| CN113087666B (zh) | 无定形喹啉甲酰胺衍生物的制备方法 | |
| Wagner et al. | Prodrugs of etilefrine: Synthesis and evaluation of 3′‐(O‐acyl) derivatives | |
| KR820002108B1 (ko) | 수용성 산성 사포닌의 제조 방법 | |
| CN114349769A (zh) | 一种头孢卡品酯e型异构体的制备方法 | |
| JP2009507014A (ja) | Ｓ−クロピドグレルの新規レジネート複合体およびその生成法 | |
| CN103159720B (zh) | 8-表-异穿心莲内酯-19-硫酸酯化物、制备方法及其制备药物用途 | |
| CN103159717B (zh) | 17-氢-9-去氢穿心莲内酯-3，19-二硫酸酯化物、制备方法及其制备药物用途 | |
| CN104906370A (zh) | 白芨丁酰胆碱酯酶抑制活性提取物及其组合物的医药用途和制备方法 | |
| CN100383149C (zh) | 一种新的晶状埃地双酯及其组合物 | |
| CN103159714B (zh) | 17-氢-9-去氢穿心莲内酯-19-硫酸酯化物、制备方法及其制备药物用途 | |
| SU786856A3 (ru) | Способ получени эсцина | |
| CN101693713A (zh) | 一种恩替卡韦的新晶型及其制备方法和药物应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: MADAUS AKTIENGESELLSCHAFT |